Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

  title={Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.},
  author={Takayuki Iwamoto and Giampaolo Bianchini and Daniel J. Booser and Yuan Qi and Charles Coutant and Christine Y. Shiang and Libero Santarpia and Junji Matsuoka and Gabriel N. Hortobagyi and William Fraser Symmans and Frankie Ann Holmes and Joyce O’Shaughnessy and Beth A. Hellerstedt and John E Pippen and Fabrice Andr{\'e} and Richard M. Simon and Lajos Pusztai},
  journal={Journal of the National Cancer Institute},
  volume={103 3},
BACKGROUND We hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers. METHODS We performed gene set analyses with BRB-ArrayTools statistical software including 2331 functionally annotated gene sets (ie, lists of genes that correspond to a particular biological pathway or biochemical function) assembled from Ingenuity Pathway Analysis and Gene Ontology databases corresponding to almost all known… 

Figures and Tables from this paper

Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer

A systems biology network-based approach may facilitate the discovery of biomarkers for predicting chemotherapy responses in breast cancer and contribute in developing personalized medicines.

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

Different processes and pathways are associated with pCR in different BC subtypes.

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status

ER-positive and ER-negative breast cancers have different biological pathways in BCBM development, and no BCBM-specific genes met the significance tests when the cancers were stratified by ER status.

Identification of key genes as potential biomarkers for triple-negative breast cancer using integrating genomics analysis

A number of key genes are identified as potential biomarkers involved in TNBC, which provide novel insights into the tumorigenesis of TNBC at the gene level and may serve as independent prognostic factors for TNBC prognosis.

Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Major transcriptomic changes induced by NAC are revealed and suggest that chemotherapy-induced gene expression changes observed early in therapy may be good predictors of response to NAC.

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer

The number of biological pathways, and therefore genes, that are associated with prognosis or treatment sensitivity are substantially larger and more consistent in ER+ cancers than among ER- tumors, which implies that it is easier to discover prognostic and predictive markers for ER+ than for ER- cancers.

Integrative analysis of survival-associated gene sets in breast cancer

The GSAS metric provided a useful medium by which it was used to identify predictive gene sets and to construct a novel gene set containing genes heavily involved in cancer progression.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.

Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17

Non-HER2 chr17 CN patterns may further predict outcome in breast cancer patients with known favorable and unfavorable prognosis, and TOP2A FISH and qPCR may not identify the same pathology on chr 17q.

DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.

DNA repair pathways can enable tumor cells to survive DNA damage induced by chemotherapy and thus provide prognostic and/or predictive value, and defects in RECQL4 impair homologous recombination, sensitizing BC cells to DNA-damaging agents.



Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer

It is shown that divergent gene sets classifying patients for the same clinical endpoint represent similar biological processes and that pathway-derived signatures can be used to predict prognosis and that the underlying biology related to aggressiveness of estrogen receptor subgroups of breast cancer is quite different.

Evaluation of biological pathways involved in chemotherapy response in breast cancer

Genes involved in the E2F3 pathway are associated with chemotherapy sensitivity among ER-negative cancers and the mutant p53-signature and expression of ER-related genes were associated with lower sensitivity to chemotherapy in ER-positive breast cancers only.

The humoral immune system has a key prognostic impact in node-negative breast cancer.

It is shown in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast.

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

  • G. BianchiniY. Qi L. Pusztai
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
Among ER-negative and ER-positive highly proliferative cancers, a subset of tumors with high expression of a B-cell/plasma cell metagene carries a favorable prognosis, and different thresholds apply in the two subgroups.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

The results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype.

Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

P53 dysfunction is prognostically most relevant in ER+ cancers and supports the hypothesis that different predictive or prognostic markers will be needed for different molecular subsets of breast cancer.

Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

This study suggests that high tau mRNA expression in ER-positive breast cancer indicates an endocrine-sensitive but chemotherapy-resistant disease, and low tau expression identifies a subset of ER- positive cancers that have poor prognosis with tamoxifen alone and may benefit from taxane-containing chemotherapy.